PT  - JOURNAL ARTICLE
AU  - Arvindra Krishnamurthy
AU  - Claire Keeble
AU  - Michelle Anderson
AU  - Kathryn Somers
AU  - Natalie Burton-Wood
AU  - Charlotte Harland
AU  - Paul Baxter
AU  - James McLenachan
AU  - Jonathan Blaxill
AU  - Daniel Blackman
AU  - Christopher Malkin
AU  - Stephen Wheatcroft
AU  - John Greenwood
TI  - 15 Clinical outcomes in patients treated with glycoprotein IIB/IIIA inhibitors during primary percutaneous coronary intervention according to arterial access site
AID  - 10.1136/heartjnl-2018-BCS.15
DP  - 2018 Jun 01
TA  - Heart
PG  - A14--A15
VI  - 104
IP  - Suppl 6
4099  - http://heart.bmj.com/content/104/Suppl_6/A14.short
4100  - http://heart.bmj.com/content/104/Suppl_6/A14.full
SO  - Heart2018 Jun 01; 104
AB  - Background There are little available contemporary real-world data in the era of third-generation P2Y12-receptor inhibitors, examining the association between glycoprotein IIb/IIIa inhibitors (GPI) and outcomes in patients undergoing primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI), according to arterial access site.Objectives We sought to investigate this association in a contemporary cohort of real-world patients.Methods Clinical and follow-up data for all patients undergoing PPCI in Leeds General Infirmary between 01–01–2009 and 31–12–2011, and 01–01–2013 and 31–12–2013 were collected prospectively. Patients included in this analysis had pre-procedural Thrombolysis in Myocardial Infarction (TIMI)−0 flow and post-procedural TIMI-3 flow in their infarct-related artery. Clinical endpoints were 30 day and 12 month mortality, and 30 day HORIZONS-major bleeding. Patients were analysed according to arterial access site with Cox-regression models, to assess the association between GPI use and outcomes in each group (transfemoral PPCI and transradial PPCI), adjusting for confounding variables.View this table:Abstract 15 Table 1 Clinical outcomes in patients treated with glycoprotein IIb/IIIa-inhibitors according to arterial access site. Data are expressed in n (%); HR: Hazard ratio; CI: Confidence interval; *p-value 0.05Results A total of 2369 patients were included in this analysis, of whom 821 (34.7%) underwent transfemoral PPCI and 1548 (65.3%) underwent transradial PPCI (Figure 1). GPI was used in 169 (20.6%) patients undergoing transfemoral PPCI, and 179 (11.6%) patients undergoing transradial PPCI. In transfemoral PPCI, GPI use was independently associated with 30 day mortality (HR 2.04 (1.05–3.94); p=0.03) and 30 day bleeding (HR 2.05 (1.07–3.93); p=0.03), particularly arterial access site bleeding (HR 2.71 (1.00–7.37); p=0.05), with no significant difference in 12 month mortality (HR 1.48 (0.82–2.67); p=0.20) (Table 1; Figures 2 (A)-(C)). However, in transradial PPCI, GPI use was not associated with 30 day (HR 1.27 (0.39–4.16); p=0.69) or 12 month (HR 1.21 (0.58–2.51); p=s0.62) mortality, or 30 day bleeding (HR 1.93 (0.73–4.76); p=0.16) (Figures 3 (A)-(C)).Conclusion In transfemoral PPCI, GPI use was independently associated with worse 30 day mortality and 30 day bleeding, particularly access-site bleeding. This association was not observed in transradial PPCI.Abstract 15 Figure 1 Inclusion algorithm for this studyAbstract 15 Figure 2 Adjusted outcomes of GPI-treated patients undergoing transfemoral PPCI (2(A)-(C)); Transradial PPCI (3(A)-(C))